Early Patient-Reported Satisfaction in Patients Initiated on Perfluorohexyloctane for Dry Eye Disease
Author(s)
Janna Manjelievskaia, MPH, PhD1, Jennifer Cheng, MS1, James Nelson, PhD1, Natalia Coenen, MPH1, Abhishek A. Nair, MS, PhD2.
1Veradigm Inc, Raleigh, NC, USA, 2Senior Manager, HEOR, Bausch & Lomb, Somerset, NJ, USA.
1Veradigm Inc, Raleigh, NC, USA, 2Senior Manager, HEOR, Bausch & Lomb, Somerset, NJ, USA.
OBJECTIVES: Dry eye disease (DED) is a chronic, multifactorial disease of the ocular surface characterized by visual discomfort, disturbance, and tear film instability. DED may interfere with activities of everyday living impacting the quality of life and well-being of the individual. Introduced in 2023, perfluorohexyloctane (PFHO) ophthalmic solution prescription eye drop for DED targets tear evaporation. We sought to characterize patient-reported satisfaction with PFHO, willingness to refill, history of over-the-counter (OTC) treatment, and concurrent assessment of refill rate.
METHODS: Adults newly initiating treatment with PFHO or another prescription DED medication were identified in the Veradigm Network EHR Database linked to claims between Sept 15, 2023 - Dec 31, 2023. Patients were contacted via the FollowMyHealth Patient Engagement Platform and recruited by email to participate in a survey. Patients were asked questions regarding satisfaction with their dry eye medication, intent to refill their current medication, and prior use of OTC eye drops. Medication refill rates were assessed via claims.
RESULTS: Of 216 DED patients responding to the survey, 22 (10.2%) patients initiated on PFHO. The mean (SD) age was 61.0 (12.9) years, majority were female (86.4%), white (77.3%), non-Hispanic (77.3%) and resided in the South (68.8%). Of these, 50.0% of the patients were “somewhat satisfied” and 31.8% were “very satisfied”. Furthermore 72.7% of the PFHO patients responded favorably towards refilling their prescription. The actual proportion of patients with at least one recorded refill was 81.8%. Most (77.3%) PFHO patients used OTC eye drops prior to initiating PFHO, with 88.2% of them on OTC eye drops for >12 months.
CONCLUSIONS: PFHO patients reported high satisfaction with their medication, with a majority refilling their prescription. Almost all PFHO patients had prior OTC eye drop usage for over 12 months, potentially identifying a subset of the patient population likely to benefit from the novel treatment.
METHODS: Adults newly initiating treatment with PFHO or another prescription DED medication were identified in the Veradigm Network EHR Database linked to claims between Sept 15, 2023 - Dec 31, 2023. Patients were contacted via the FollowMyHealth Patient Engagement Platform and recruited by email to participate in a survey. Patients were asked questions regarding satisfaction with their dry eye medication, intent to refill their current medication, and prior use of OTC eye drops. Medication refill rates were assessed via claims.
RESULTS: Of 216 DED patients responding to the survey, 22 (10.2%) patients initiated on PFHO. The mean (SD) age was 61.0 (12.9) years, majority were female (86.4%), white (77.3%), non-Hispanic (77.3%) and resided in the South (68.8%). Of these, 50.0% of the patients were “somewhat satisfied” and 31.8% were “very satisfied”. Furthermore 72.7% of the PFHO patients responded favorably towards refilling their prescription. The actual proportion of patients with at least one recorded refill was 81.8%. Most (77.3%) PFHO patients used OTC eye drops prior to initiating PFHO, with 88.2% of them on OTC eye drops for >12 months.
CONCLUSIONS: PFHO patients reported high satisfaction with their medication, with a majority refilling their prescription. Almost all PFHO patients had prior OTC eye drop usage for over 12 months, potentially identifying a subset of the patient population likely to benefit from the novel treatment.
Conference/Value in Health Info
2025-05, ISPOR 2025, Montréal, Quebec, CA
Value in Health, Volume 28, Issue S1
Code
PCR52
Topic
Patient-Centered Research
Topic Subcategory
Patient-reported Outcomes & Quality of Life Outcomes
Disease
SDC: Sensory System Disorders (Ear, Eye, Dental, Skin)